Aegate is an expert in the digital authentication of medicines. We have developed tried and tested technology that provides the high performing authentication service that NMVOs require to keep patients safe from falsified and expired medicines, across Europe.
Each year in Europe 10 billion medicine packs are dispensed. Under the Falsified Medicines Directive (FMD) each one will need to be checked in real time, in all dispensing environments.
Aegate has extensive experience with over 10 years of continuous operational service that has seen 3.9 billion packs scanned. This means that we are acknowledged as authentication specialists. We are professionals in Blueprint with an existing, fully functioning solution.
We are able to demonstrate:
The FMD Clock is ticking
With the publication of the Delegated Regulation on February 9 2020 the time available to implement the Falsified Medicines Directive reduces every day. That is less time to connect 170,000 pharmacies, less time to test, less time to be ready to scan 10 billion packs every year and less time to protect the 500 million citizens of Europe.
The Aegate NMVO Stakeholder Guide – are you asking the right questions?
Our expert advice for stakeholders forming their local NMVO can be found here. Ensure your country’s Authentication Service is the best in can be in terms of security, compliance, operation and governance.
The Aegate Blueprint solution delivers clear advantages for the NMVOs:
Aegate is an EMVO appointed Blueprint provider. The Aegate Blueprint solution is highly secure and resilient, because it is hosted on a private cloud, which delivers 100% availability. It is performance proven with a well-established test harness an intuitive reporting.
According to The European Observatory on Infringements of Intellectual Property Rights (EUIPO) fake drugs cost the EU pharmaceutical industry €10.2bn annually. In their recently published report, that refers to manufacturers and wholesalers but not retailers, The Observatory estimates that the loss of sales in the sector is equivalent, in direct employment losses, of almost 38,000 jobs. The report also highlights the serious consequences for health that fake drugs can have on patients across Europe. These health issues also have economic implications, especially on healthcare systems. For more information, see the full report here.
This risk to health is why the EU Parliament have taken action to introduce the Falsified Medicines Directive, which needs to be implemented by February 2019, to help to secure the pharmaceutical supply chain from the dangers of falsified medicines.